This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Various				
Dyslipidemia; diabetes	Peroxisome proliferation-activated receptor- α (PPARA; PPAR α)	<p><i>In vitro</i> studies identified a new class of fibrate-based PPARα agonists that could help treat dyslipidemia. In two cell-based assays, low micromolar concentrations of an analog of clofibril acid agonized PPARα. The compound also increased expression of a PPARα target gene by twofold and had greater selectivity for PPARα than clofibril acid. Ongoing work includes pharmacokinetic and <i>in vivo</i> efficacy studies of several potent clofibril acid analogs.</p> <p>Zydus Cadila Group's ZYH1, an agonist of PPARα and PPARγ, is in Phase III testing to treat dyslipidemia. Kyorin Pharmaceutical Co. Ltd.'s PPARα agonist, KRP-101, has completed Phase IIa testing to treat dyslipidemia. Chiglitazar (CS038), a PPARα agonist from Shenzhen Chipscreen Biosciences Ltd., has completed Phase IIa testing to treat diabetes.</p> <p>SciBX 2(40); doi:10.1038/scibx.2009.1516 Published online Oct. 15, 2009</p>	Unpatented; unlicensed	<p>Giampietro, L. <i>et al. J. Med. Chem.</i>; published online Sept. 30, 2009; doi:10.1021/jm900878u</p> <p>Contact: Rosa Amoroso, G. d'Annunzio University, Chieti, Italy e-mail: ramoroso@unich.it</p>